cardiac myopathy

Bristol Myers backs up its case for heart drug mavacamten as FDA weighs app in cardiomyopathy
Endpoints
Sat, 05/15/21 - 10:58 pm
Bristol Myers Squibb
mavacamten
FDA
cardiac myopathy